These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 12820313)
1. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313 [TBL] [Abstract][Full Text] [Related]
2. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312 [TBL] [Abstract][Full Text] [Related]
3. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802 [TBL] [Abstract][Full Text] [Related]
4. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
5. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648 [TBL] [Abstract][Full Text] [Related]
6. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Hardt PD; Ewald N Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806 [TBL] [Abstract][Full Text] [Related]
7. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Schneider J; Bitterlich N; Schulze G Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052 [TBL] [Abstract][Full Text] [Related]
8. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Shastri YM; Povse N; Schröder O; Stein J Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497 [No Abstract] [Full Text] [Related]
9. [Comparison of different stool tests for the detection of cancer of the colon]. Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820 [TBL] [Abstract][Full Text] [Related]
10. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916 [TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Schneider J; Schulze G Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971 [TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer]. Li Y; Wang JJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720 [TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer. Ervens J; Fuchs H; Niemann VT; Hoffmeister B J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718 [TBL] [Abstract][Full Text] [Related]
14. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
15. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma]. Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373 [TBL] [Abstract][Full Text] [Related]
16. [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study]. Naumann M; Schaum B; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J Dtsch Med Wochenschr; 2004 Aug; 129(34-35):1806-7. PubMed ID: 15314744 [No Abstract] [Full Text] [Related]
17. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469 [TBL] [Abstract][Full Text] [Related]